A Placebo-Controlled Study for SPM 962 in Restless Legs Syndrome (RLS) Patients
Status:
Completed
Trial end date:
2009-08-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to investigate efficacy and safety of SPM 962 in
Japanese RLS patients in a multi-center, placebo-controlled double-blind parrallel group
comparative study following once-daily multiple transdermal doses of SPM 962 within a range
of 2.25 to 6.75 mg/day. Recommended maintainance dose range is also to be investigated.